Dental Journal of Advance Studies

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  12 (2024)
Volume  11 (2023)
Volume  10 (2022)
Volume  9 (2021)
Volume  8 (2020)
Volume  7 (2019)
Volume  6 (2018)
Volume  5 (2017)
Volume  4 (2016)
Volume  3 (2015)
Volume  2 (2014)
Volume  1 (2013)
Related articles

VOLUME 12 , ISSUE 1 ( January-April, 2024 ) > List of Articles

REVIEW ARTICLE

Managing Periodontitis with Host Modulation Therapy: Current Concept and Future Perspective

Nidhi Chandel, Ajay Mahajan, Kanwarjit S Asi, Monika S Walhe

Keywords : Host modulating agents, Host modulation, Pathogenesis of periodontitis, Periodontology

Citation Information : Chandel N, Mahajan A, Asi KS, Walhe MS. Managing Periodontitis with Host Modulation Therapy: Current Concept and Future Perspective. 2024; 12 (1):29-33.

DOI: 10.5005/djas-11014-0035

License: CC BY-NC-ND 4.0

Published Online: 30-04-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

As our basic knowledge of the etiopathogenesis of periodontitis has improved over the past years, it has become evident that the periodontal disease is multifactorial disease caused by the bacteria which establishes the immune reaction in the host. This initiation of the host response leads to destruction of the surrounding periodontium which ultimately results in tooth loss. An ever-increasing research in the field of pathogenesis of periodontitis has revealed that the initial breakdown in chronic inflammatory periodontal disease often involves a failure of resolution pathways in order to restore host's homeostasis. The practice of modulating the host response to control periodontal disease has been employed for many years not only for the periodontal disease but also for various medical conditions. As a result, the goal of this review is to provide an overview of existing findings on host modulation therapies (HMTs). In addition, to describe some of the recent advances made over the years in the field of HMTs and to determine some pertinent conclusions about its involvement in disease development and its use in clinical therapy. This will provide a chance for more detailed investigation in this particular field. As a result, the goal of this review is to describe the current findings available in the literature on HMT.

HTML PDF Share
  1. Socransky SS, Haffajee AD. Evidence of bacterial etiology: A historical perspective. Periodontol 2000 1994;5:7–25. DOI: 10.1111/j.1600-0757.1994.tb00016.x.
  2. Bartold PM, Van Dyke TE. Periodontitis: A host-mediated disruption of microbial homeostasis. Unlearning learned concepts. Periodontol 2000 2013;62(1):203–217. DOI: 10.1111/j.1600-0757.2012.00450.x.
  3. Page RC, Kornman KS. The pathogenesis of human periodontitis: An introduction. Periodontol 2000 1997;14:9–11. DOI: 10.1111/j.1600-0757.1997.tb00189.x.
  4. Hajishengallis G, Chavakis T, Lambris JD. Current understanding of periodontal disease pathogenesis and targets for host-modulation therapy. Periodontol 2000 2020;84(1):14–34. DOI: 10.1111/prd. 12331.
  5. Preshaw PM. Host response modulation in periodontics. Periodontol 2000 2008;48:92–110. DOI: 10.1111/j.1600-0757.2008.00252.x.
  6. Geisinger ML, Holmes CM, Vassilopoulos PJ, et al. Adjunctive treatment of chronic periodontitis with systemic low-dose aspirin therapy. Clin Adv Periodont 2012;2(3):195–199. DOI: 10.1902/cap.2012.120022.
  7. Golub LM, Ciancio S, Ramamurthy NS, et al. Low-dose doxycycline therapy: Effect on gingival and crevicular fluid collagenase activity in humans. J Periodont Res 1990;25(6):321–330. DOI: 10.1111/J.1600-0765.1990.TB00923.X.
  8. Graves DT, Cochran D. The contribution of interleukin-1 and tumor necrosis factor to periodontal tissue destruction. J Periodontol 2003;74(3):391–401. DOI: 10.1902/jop.2003.74.3.391.
  9. Nath SG, Raveendran R. Microbial dysbiosis in periodontitis. J Indian Soc Periodontol 2013;17(4):543–545. DOI: 10.4103/0972-124X. 118334.
  10. Riccelli AE, Agarwal S, Piesco NP, et al. Role of cytokines in periodontal diseases. J Calif Dent Assoc 1995;23(8):48–51. PMID: 9064366.
  11. Ryan ME, Golub LM. Modulation of matrix metalloproteinase activities in periodontitis as a treatment strategy. Periodontol 2000 2000;24:226–238. DOI: 10.1034/j.1600-0757.2000.2240111.x.
  12. Ipshita S, Kurian IG, Dileep P, et al. Host modulation therapy: An updated review. J Adv Clin Res Insights 2017;4(2):55–58. DOI: 10.15713/ins.jcri.157.
  13. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: Dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008;8(5):349–361. DOI: 10.1038/nri2294.
  14. Janakiram NB, Rao CV. Role of lipoxins and resolvins as anti-inflammatory and proresolving mediators in colon cancer. Curr Mol Med 2009;9(5):565–579. DOI: 10.2174/156652409788488748.
  15. Brennan PA, Thomas GJ, Langdon JD. The role of nitric oxide in oral diseases. Arch Oral Biol 2003;48(2):93–100. DOI: 10.1016/s0003-9969(02)00183-8.
  16. Zingarelli B, Southan GJ, Gilad E, et al. The inhibitory effects of mercaptoalkylguanidines on cyclo-oxygenase activity. Br J Pharmacol 1997;120(3):357–366. DOI: 10.1038/sj.bjp.0700892.
  17. Lohinai Z, Stachlewitz R, Virág L, et al. Evidence for reactive nitrogen species formation in the gingivomucosal tissue. J Dent Res 2001;80(2):470–475. DOI: 10.1177/00220345010800021401.
  18. Weinreb M, Quartuccio H, Seedor JG, et al. Histomorphometrical analysis of the effects of the bisphosphonate alendronate on bone loss caused by experimental periodontitis in monkeys. J Periodontal Res 1994;29(1):35–40. DOI: 10.1111/j.1600-0765.1994.tb01088.x.
  19. Crotti T, Smith MD, Hirsch R, et al. Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. J Periodontal Res 2003;38(4):380–387. DOI: 10.1034/j.1600-0765.2003.00615.x.
  20. Howell TH, Williams RC. Nonsteroidal antiinflammatory drugs as inhibitors of periodontal disease progression. Crit Rev Oral Biol Med 1993;4(2):177–196. DOI: 10.1177/10454411930040020301.
  21. Buduneli N, Vardar S, Atilla G, et al. Gingival crevicular fluid matrix metalloproteinase-8 levels following adjunctive use of meloxicam and initial phase of periodontal therapy. J Periodontol 2002;73(1): 103–109. DOI: 10.1902/jop.2002.73.1.103.
  22. Williams RC. Periodontal disease. N Engl J Med 1990;322(6):373–382. DOI: 10.1056/NEJM199002083220606.
  23. El-Shinnawi UM, El-Tantawy SI. The effect of alendronate sodium on alveolar bone loss in periodontitis (clinical trial). J Int Acad Periodontol 2003;5(1):5–10. PMID: 12666950.
  24. Burns FR, Stack MS, Gray RD, et al. Inhibition of purified collagenase from alkali-burned rabbit corneas. Invest Ophthalmol Vis Sci 1989;30(7):1569–1575. PMID: 2545645.
  25. Golub LM, Wolff M, Lee HM, et al. Further evidence that tetracyclines inhibit collagenase activity in human crevicular fluid and from other mammalian sources. J Periodontal Res 1985;20(1):12–23. DOI: 10.1111/j.1600-0765.1985.tb00405.x.
  26. Epstein NE. Complications due to the use of BMP/INFUSE in spine surgery: The evidence continues to mount. Surg Neurol Int 2013;4(Suppl 5):S343–S352. DOI: 10.4103/2152-7806.114813.
  27. Ling MR, Chapple IL, Matthews JB. Peripheral blood neutrophil cytokine hyper-reactivity in chronic periodontitis. Innate Immun 2015;21(7):714–725. DOI: 10.1177/1753425915589387.
  28. Van Dyke TE. Pro-resolving mediators in the regulation of periodontal disease. Mol Aspects Med 2017;58:21–36. DOI: 10.1016/j.mam.2017.04.006.
  29. Kohli P, Levy BD. Resolvins and protectins: Mediating solutions to inflammation. Br J Pharmacol 2009;158(4):960–971. DOI: 10.1111/j.1476-5381.2009.00290.x.
  30. Gatej S, Gully N, Gibson R, et al. Probiotics and Periodontitis - A Literature Review. J Int Acad Periodontol 2017;19(2):42–50. PMID: 31473722.
  31. Kobayashi R, Kobayashi T, Sakai F, et al. Oral administration of Lactobacillus gasseri SBT2055 is effective in preventing Porphyromonas gingivalis-accelerated periodontal disease. Sci Rep 2017;7(1):545. DOI: 10.1038/s41598-017-00623-9.
  32. Maekawa T, Hajishengallis G. Topical treatment with probiotic Lactobacillus brevis CD2 inhibits experimental periodontal inflammation and bone loss. J Periodontal Res 2014;49(6):785–791. DOI: 10.1111/jre.12164.
  33. Martin-Cabezas R, Davideau JL, Tenenbaum H, et al. Clinical efficacy of probiotics as an adjunctive therapy to non-surgical periodontal treatment of chronic periodontitis: A systematic review and meta-analysis. J Clin Periodontol 2016;43(6):520–530. DOI: 10.1111/jcpe.12545.
  34. Maekawa T, Abe T, Hajishengallis E, et al. Genetic and intervention studies implicating complement C3 as a major target for the treatment of periodontitis. J Immunol 2014;192(12):6020–6027. DOI: 10.4049/jimmunol.1400569.
  35. Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol 2013;190(8):3831–3838. DOI: 10.4049/jimmunol.1203487.
  36. Mastellos DC, Ricklin D, Hajishengallis E, et al. Complement therapeutics in inflammatory diseases: Promising drug candidates for C3-targeted intervention. Mol Oral Microbiol 2016;31(1):3–17. DOI: 10.1111/omi.12129.
  37. Goodridge HS, Ahmed SS, Curtis N, et al. Harnessing the beneficial heterologous effects of vaccination. Nat Rev Immunol 2016;16(6):392–400. DOI: 10.1038/nri.2016.43.
  38. Rajapakse PS, O'Brien-Simpson NM, Slakeski N, et al. Immunization with the RgpA-Kgp proteinase-adhesin complexes of Porphyromonas gingivalis protects against periodontal bone loss in the rat periodontitis model. Infect Immun 2002;70(5):2480–2486. DOI: 10.1128/IAI.70.5.2480-2486.2002.
  39. Maeda K, Kobayashi Y, Koide M, et al. The regulation of bone metabolism and disorders by Wnt signaling. Int J Mol Sci 2019;20(22):5525. DOI: 10.3390/ijms20225525.
  40. Aral K, Milward MR, Kapila Y, et al. Inflammasomes and their regulation in periodontal disease: A review. J Periodontal Res 2020;55(4): 473–487. DOI: 10.1111/jre.12733.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.